Biotechnology

Mahzi Therapeutics has dosed its first patient in a landmark study, offering a potential breakthrough for a rare and severe neurogenetic disorder.

Amid a surge in MedTech M&A, Piper Sandler appoints 25-year veteran Aamer Naseer to steer its life sciences outsourcing and B2B technology groups.

At Expo West, GELITA unveils advanced collagen solutions, including OPTIBAR®, tackling major challenges in the booming high-protein, low-sugar snack market.

Curanex Pharmaceuticals hits a key manufacturing milestone for Phyto-N, a botanical drug with a 30-year history, advancing its quest for FDA approval.

With promising preclinical data and Australian trial approval, Kivu’s KIVU-305 aims to overcome past failures in targeting aggressive solid tumors.

Rgenta Therapeutics unveils a promising oral drug that targets the genetic root of Huntington's, offering a new beacon of hope for patients.

New subgroup data from ITM's COMPETE trial could refine treatment for a tough-to-treat cancer and bolster the company's position in the radiopharma market.

Investors sue Corcept Therapeutics, claiming the company hid FDA warnings about its key drug, relacorilant, before a 50% stock price collapse.

P4ML joins the Orphan Therapeutics Accelerator to bring shelved cures to patients, leveraging a new non-profit model and expanding access to the MENA region.

With a key gene therapy approval imminent and major clinical data on deck, REGENXBIO's upcoming financial report will be a crucial test for the biotech.

Flush with cash and nearing major clinical milestones for its neuromuscular disease pipeline, Dyne Therapeutics is set to make its case to investors.

As Aura presents its precision oncology pipeline at key conferences, investors will weigh the promise of its lead drug against a challenging financial landscape.

With its new HAE drug EKTERLY® smashing revenue forecasts, KalVista heads to key conferences where investors will scrutinize its path to profitability.

A novel nasal spray for progressive MS shows it can calm brain inflammation and boost neuroprotection, offering new hope for a difficult-to-treat disease.

With its stock lagging, TScan Therapeutics will use a key conference to highlight upcoming clinical trial data and convince investors of its pipeline's value.

With $400M in 2025 sales, Immunocore now leverages its KIMMTRAK success to fund a high-stakes pivot into broader cancers, HIV, and autoimmune disease.

With the appointment of TechTarget co-founder Don Hawk, Life Science Connect is set to import a proven B2B intent data playbook into the life sciences.

With sales rising and key FDA milestones met, Australian biotech Immuron resets its strategy, seeking partners to fund its promising infectious disease pipeline.

New research reveals how stomach cancer cells hijack healthy tissue to build supportive 'nests' in distant organs, opening a new front in the war on metastasis.

New FDA-cleared Persona PLUS technology promises to increase plasma yields per donor, tackling the growing global demand for life-saving therapies.